1626387-81-2

Basic information

• Product Name: (R)-4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl 2,4-dimethylpiperazine-1-carboxylate hydrochloride salt
• Synonyms: (R)-4-((3-chloro-2-fluorophenyl)amino);1-Piperazinecarboxylic acid, 2,4-dimethyl-, 4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl ester, hydrochloride (1:1), (2R);(R)-4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl 2,4-dimethylpiperazine-1-carboxylate hydrochloride salt ISO 9001：2015 REACH
• CAS NO: 1626387-81-2
• Molecular Weight: 0
• Mol File: 1626387-81-2.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl 2,4-dimethylpiperazine-1-carboxylate hydrochloride salt(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl 2,4-dimethylpiperazine-1-carboxylate hydrochloride salt(1626387-81-2)
• EPA Substance Registry System: (R)-4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl 2,4-dimethylpiperazine-1-carboxylate hydrochloride salt(1626387-81-2)

Safety Data

• Hazardous Substances Data: 1626387-81-2(Hazardous Substances Data)

Usage

General Description

The chemical "(R)-4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl 2,4-dimethylpiperazine-1-carboxylate hydrochloride salt" is a complex compound with multiple functional groups. It consists of a quinazoline ring with a 7-methoxy and 3-chloro-2-fluorophenyl substitution, combined with a 2,4-dimethylpiperazine-1-carboxylate group. Additionally, the compound is in the form of a hydrochloride salt. This chemical structure suggests its potential use in pharmaceuticals, as quinazoline derivatives are of interest due to their wide range of biological activities, including antitumor and antimicrobial properties. The presence of a piperazine group also indicates potential interactions with biological receptors or enzymes.

Upstream product

• 612501-80-1 4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl acetate monohydrochloride 
• 2106-04-9 3-chloro-2-fluoroaniline 
• 740081-22-5 4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl acetate 
• 230955-75-6 6-acetoxy-4-chloro-7-methoxyquinazoline 
• 179688-53-0 (4-hydroxy-7-methoxyquinazolin-6-yl) acetate 
• 179688-52-9 4,6-dihydroxy-7-methoxyquinazoline 
• 1626387-80-1 (R)-4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl-2,4-dimethylpiperazinyl-1-carboxylic acid ester 

Relevant articles and documents

Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Recent reports suggest that an increasing number of patients with lung cancer, especially those with activating mutations of the epidermal growth factor receptor (EGFR), also present with brain metastases and leptomeningeal metastases. These patients have poor prognosis as there are no approved drugs for these indications. Available agents have poor efficacy for these patients even at well above their standard dose. Herein, we report the discovery of (4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl (2R)-2,4-dimethylpiperazine-1-carboxylate 1m (AZD3759), an investigational drug currently in Phase 1 clinical trial, which has excellent central nervous system penetration and which induces profound regression of brain metastases in a mouse model.

Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor

The invention relates to compounds of formula (I), or a pharmaceutically acceptable salt thereof: which possess inhibitory activity against activating mutant forms of EGFR, and are accordingly useful for their anti-cancer activity and in methods of treatment of the human or animal body. The invention also relates pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.